Prostate Cancer Risk Stratification by Digital Histopathology and Deep Learning.

IF 3.3 Q2 ONCOLOGY JCO Clinical Cancer Informatics Pub Date : 2024-06-01 DOI:10.1200/CCI.23.00184
Yanan Shao, Roozbeh Bazargani, Davood Karimi, Jane Wang, Ladan Fazli, S Larry Goldenberg, Martin E Gleave, Peter C Black, Ali Bashashati, Septimiu Salcudean
{"title":"Prostate Cancer Risk Stratification by Digital Histopathology and Deep Learning.","authors":"Yanan Shao, Roozbeh Bazargani, Davood Karimi, Jane Wang, Ladan Fazli, S Larry Goldenberg, Martin E Gleave, Peter C Black, Ali Bashashati, Septimiu Salcudean","doi":"10.1200/CCI.23.00184","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Prostate cancer (PCa) represents a highly heterogeneous disease that requires tools to assess oncologic risk and guide patient management and treatment planning. Current models are based on various clinical and pathologic parameters including Gleason grading, which suffers from a high interobserver variability. In this study, we determine whether objective machine learning (ML)-driven histopathology image analysis would aid us in better risk stratification of PCa.</p><p><strong>Materials and methods: </strong>We propose a deep learning, histopathology image-based risk stratification model that combines clinicopathologic data along with hematoxylin and eosin- and Ki-67-stained histopathology images. We train and test our model, using a five-fold cross-validation strategy, on a data set from 502 treatment-naïve PCa patients who underwent radical prostatectomy (RP) between 2000 and 2012.</p><p><strong>Results: </strong>We used the concordance index as a measure to evaluate the performance of various risk stratification models. Our risk stratification model on the basis of convolutional neural networks demonstrated superior performance compared with Gleason grading and the Cancer of the Prostate Risk Assessment Post-Surgical risk stratification models. Using our model, 3.9% of the low-risk patients were correctly reclassified to be high-risk and 21.3% of the high-risk patients were correctly reclassified as low-risk.</p><p><strong>Conclusion: </strong>These findings highlight the importance of ML as an objective tool for histopathology image assessment and patient risk stratification. With further validation on large cohorts, the digital pathology risk classification we propose may be helpful in guiding administration of adjuvant therapy including radiotherapy after RP.</p>","PeriodicalId":51626,"journal":{"name":"JCO Clinical Cancer Informatics","volume":"8 ","pages":"e2300184"},"PeriodicalIF":3.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371114/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Clinical Cancer Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/CCI.23.00184","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Prostate cancer (PCa) represents a highly heterogeneous disease that requires tools to assess oncologic risk and guide patient management and treatment planning. Current models are based on various clinical and pathologic parameters including Gleason grading, which suffers from a high interobserver variability. In this study, we determine whether objective machine learning (ML)-driven histopathology image analysis would aid us in better risk stratification of PCa.

Materials and methods: We propose a deep learning, histopathology image-based risk stratification model that combines clinicopathologic data along with hematoxylin and eosin- and Ki-67-stained histopathology images. We train and test our model, using a five-fold cross-validation strategy, on a data set from 502 treatment-naïve PCa patients who underwent radical prostatectomy (RP) between 2000 and 2012.

Results: We used the concordance index as a measure to evaluate the performance of various risk stratification models. Our risk stratification model on the basis of convolutional neural networks demonstrated superior performance compared with Gleason grading and the Cancer of the Prostate Risk Assessment Post-Surgical risk stratification models. Using our model, 3.9% of the low-risk patients were correctly reclassified to be high-risk and 21.3% of the high-risk patients were correctly reclassified as low-risk.

Conclusion: These findings highlight the importance of ML as an objective tool for histopathology image assessment and patient risk stratification. With further validation on large cohorts, the digital pathology risk classification we propose may be helpful in guiding administration of adjuvant therapy including radiotherapy after RP.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通过数字组织病理学和深度学习进行前列腺癌风险分层。
目的:前列腺癌(PCa)是一种高度异质性疾病,需要各种工具来评估肿瘤风险并指导患者管理和治疗计划。目前的模型基于各种临床和病理参数,包括格里森分级,而格里森分级在观察者之间存在很大的差异性。在本研究中,我们将确定客观的机器学习(ML)驱动的组织病理学图像分析是否能帮助我们更好地对PCa进行风险分层:我们提出了一种基于组织病理学图像的深度学习风险分层模型,该模型结合了临床病理学数据以及苏木精、伊红和 Ki-67 染色的组织病理学图像。我们采用五倍交叉验证策略,在 2000 年至 2012 年间接受根治性前列腺切除术(RP)的 502 名未接受过治疗的 PCa 患者的数据集上训练和测试了我们的模型:我们使用一致性指数来评估各种风险分层模型的性能。与格里森分级和前列腺癌术后风险评估风险分层模型相比,我们基于卷积神经网络的风险分层模型表现更优。使用我们的模型,3.9%的低风险患者被正确地重新分类为高风险,21.3%的高风险患者被正确地重新分类为低风险:这些发现凸显了 ML 作为组织病理学图像评估和患者风险分层客观工具的重要性。如果在大样本人群中得到进一步验证,我们提出的数字病理学风险分类可能有助于指导辅助治疗的实施,包括RP术后的放疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.20
自引率
4.80%
发文量
190
期刊最新文献
Development, Validation, and Clinical Utility of Electronic Patient-Reported Outcome Measure-Enhanced Prediction Models for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy. Metastatic Versus Localized Disease as Inclusion Criteria That Can Be Automatically Extracted From Randomized Controlled Trials Using Natural Language Processing. Identifying Oncology Patients at High Risk for Potentially Preventable Emergency Department Visits Using a Novel Definition. Use of Patient-Reported Outcomes in Risk Prediction Model Development to Support Cancer Care Delivery: A Scoping Review. Optimizing End Points for Phase III Cancer Trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1